Saturday 17 October 2026 Export LNSR’s income statement to Excel — free account

LENSAR, Inc.

LENSAR, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $58.4 million, up 9.24% from fiscal 2024. In the quarter to June 2026, revenue grew 18.4%, EPS grew 291.7% and free cash flow grew 96.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

5.80 0.23 −3.81%

Follow LNSR

Alert me

Market cap: $74.1M
P/E: 2.0×
Fwd P/E: 7.1×
Dividend yield: —
F-score: 3/9
Altman Z: −2.84
Beneish M: −4.30
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 19.98%

Capital & Financial Ratios $m

Market Cap 74.09

Revenue 60.26

Net Income 34.70

Free Cash Flow (7.40)

Net Debt (13.56)

Current Ratio 2.39

Debt/Equity 0.00

P/E ratio 2.04

Fwd P/E 7.13

P/S ratio 1.18

P/B ratio 4.79

Past 5Y EPS Growth —

This Y EPS Growth 100.35%

Next Y EPS Growth (2,350.00%)

Next Y revenue growth 4.90%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 30.39%

10-year low 10-year high

P/B against its own 10 years 85.78%

10-year low 10-year high

EV/Sales against its own 10 years 44.85%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	24	22	18	14
Receivables	4	6	6	6
Inventory	16	11	22	25
Other	—	—	—	—
	46	42	47	47

	2023	2024	2025	Q'26
Payables	4	6	19	11
ST’ Debt	—	—	—	—
Other	—	—	10	—
	12	15	41	20

Compound Annual Growth %

	10y	5y	3y
Sales	—	17.24%	18.23%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	13	16	—	—	—
’25	14	14	14	16	58
’24	11	13	14	17	53
’23	8	12	10	12	42
’22	9	8	8	10	35
’21	7	8	8	11	34
’20	6	5	7	8	26

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	0	—	—	—
’25	(7)	(5)	(4)	1	(15)
’24	(5)	(4)	3	4	(2)
’23	(7)	(2)	0	0	(10)
’22	(3)	(3)	(5)	(5)	(15)
’21	(5)	(1)	(2)	(1)	(9)
’20	(6)	(5)	0	(2)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	0	—	—	—
’25	(7)	(5)	(4)	1	(15)
’24	(5)	(4)	3	4	(2)
’23	(7)	(2)	0	(1)	(10)
’22	(3)	(3)	(5)	(5)	(15)
’21	(5)	(1)	(2)	(1)	(9)
’20	(6)	(6)	0	(2)	(14)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	2.36	0.15	—	—	—
’25	(2.32)	(0.15)	(0.31)	(0.12)	(2.87)
’24	(0.19)	(0.79)	(0.13)	(1.61)	(2.73)
’23	(0.40)	(0.81)	0.21	(0.35)	(1.31)
’22	(0.67)	(0.67)	(0.39)	(0.24)	(1.96)
’21	(0.56)	(0.47)	(0.65)	(0.41)	(2.09)
’20	(3.44)	(4.20)	(0.64)	(0.78)	(4.28)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	3.16	5.82	2.15	1.80	2.67	7.25	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	12.71	9.83	8.80	4.49	9.23	17.31
People
People	Employees	—	—	—	75	100	110	110	130	140	150
	Revenue/emp, $m	—	—	0.00	0.41	0.26	0.31	0.32	0.32	0.38	0.39
Income, $m
Income, $m	Revenue	—	—	24	31	26	34	35	42	53	58
	Gross margin, %	—	—	44.07	43.33	53.35	51.75	56.44	50.06	48.33	46.41
	EBT	—	—	(13)	(15)	(20)	(20)	(20)	(14)	(31)	(34)
	EBT margin, %	—	—	(51.55)	(48.01)	(74.95)	(56.88)	(56.32)	(34.11)	(58.71)	(58.66)
	Net income	—	0	(13)	(15)	(20)	(20)	(20)	(14)	(31)	(34)
	Depreciation	—	—	5	4	3	3	3	4	4	4
Per share, $
Per share, $	Revenue	—	—	22.79	28.53	5.71	3.68	3.48	3.84	4.64	4.89
	Earnings	—	—	(11.77)	(13.70)	(4.28)	(2.09)	(1.96)	(1.31)	(2.73)	(2.87)
	Cash flow	—	—	(1.76)	(11.77)	(2.98)	(0.96)	(1.46)	(0.88)	(0.20)	(1.24)
	Capex	—	—	(3.04)	(1.95)	(0.07)	(0.04)	(0.01)	(0.02)	(0.01)	(0.01)
	Free cash flow	—	—	(4.80)	(13.72)	(3.05)	(0.99)	(1.47)	(0.90)	(0.21)	(1.25)
	Book value	—	—	(19.13)	(28.55)	14.54	5.85	4.13	3.05	0.42	(2.18)
	Shares, m	—	—	1	1	5	9	10	11	12	12
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	2.53	2.53	1.27	1.63	0.78	1.05	1.92	2.38
	P/B	—	—	0.97	0.97	0.50	1.02	0.66	1.33	21.18	0.00
	EV/Sales	—	—	1.16	1.16	(0.03)	0.89	0.55	0.63	1.62	2.18
	EV/FCF	—	—	(1.63)	(1.63)	0.06	(3.31)	(1.29)	(2.69)	(35.72)	(8.54)
Cash, $m
Cash, $m	Operating cash flow	—	—	(2)	(13)	(14)	(9)	(15)	(10)	(2)	(15)
	Capex	—	—	(3)	(2)	0	0	0	0	0	0
	Free cash flow	—	—	(5)	(15)	(14)	(9)	(15)	(10)	(2)	(15)
Balance, $m
Balance, $m	Working capital	—	—	4	9	50	36	22	35	27	6
	Total debt	—	—	6	20	3	3	2	—	—	—
	Net debt	—	—	3	16	(41)	(32)	(15)	(24)	(22)	(18)
	Shareholders’ equity	—	—	(20)	(31)	67	55	42	33	5	(26)
Returns, %
Returns, %	ROA	—	—	(97.24)	(46.22)	(34.80)	(26.93)	(32.56)	(22.93)	(46.22)	(49.78)
	ROIC	—	—	0.00	0.00	(43.45)	(52.85)	(46.18)	(81.61)	0.00	0.00
	ROE	—	—	55.06	57.46	(107.89)	(32.11)	(41.12)	(38.14)	(164.03)	324.05

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)	Compare
HYPR Hyperfine, Inc.	$82.7M	— (loss-making)	— (loss-making)	+44.81% (above 0%: growing)	n/m	+13.43% (above 0%: growing)	50.72%	(216.93%)	Compare
SERA Sera Prognostics, Inc.	$80.1M	— (loss-making)	— (loss-making)	+76.47% (above 0%: growing)	n/m	−10.58% (below 0%: shrinking)	(66.67%)	(33,346.67%)	Compare
LUNG Pulmonx Corporation	$79.5M	— (loss-making)	— (loss-making)	−4.62% (below 0%: shrinking)	n/m	−31.79% (below 0%: shrinking)	77.97%	(39.80%)	Compare
OM Outset Medical, Inc.	$76.6M	— (loss-making)	— (loss-making)	+0.69% (above 0%: growing)	n/m	−90.54% (below 0%: shrinking)	41.99%	(49.55%)	Compare
ECOR electroCore, Inc.	$75.3M	— (loss-making)	— (loss-making)	+28.03% (above 0%: growing)	n/m	−443.52% (below 0%: shrinking)	86.53%	(29.33%)	Compare
LNSR LENSAR, Inc.	$74.1M	2.0×	7.1×	+18.37% (above 0%: growing)	n/m	+96.81% (above 0%: growing)	59.27%	12.94%
MYO Myomo, Inc.	$51.5M	— (loss-making)	— (loss-making)	+21.26% (above 0%: growing)	n/m	+80.02% (above 0%: growing)	72.13%	(19.26%)	Compare
Median of peers	$79.8M	—	—	+27.39%	—	−8.81%	57.12%	(46.24%)

All 149 Medical Devices stocks →

LENSAR, Inc. (LNSR) key facts

Strength: LENSAR, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $58.4 million, up 9.24% from fiscal 2024.
LENSAR, Inc. (LNSR) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LNSR traded at $5.80, a market capitalization of $74.1 million.
Return on equity was 324.1% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −2.84 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.